Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. 1991

E P Sampaio, and E N Sarno, and R Galilly, and Z A Cohn, and G Kaplan
Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, New York 10021.

Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when these cells are triggered with lipopolysaccharide and other agonists in culture. 40% inhibition occurs at the clinically achievable dose of the drug of 1 micrograms/ml. In contrast, the amount of total protein and individual proteins labeled with [35S]methionine and expressed on SDS-PAGE are not influenced. The amounts of interleukin 1 beta (IL-1 beta), IL-6, and granulocyte/macrophage colony-stimulating factor produced by monocytes remain unaltered. The selectivity of this drug may be useful in determining the role of TNF-alpha in vivo and modulating its toxic effects in a clinical setting.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D004731 Endotoxins Toxins closely associated with the living cytoplasm or cell wall of certain microorganisms, which do not readily diffuse into the culture medium, but are released upon lysis of the cells. Endotoxin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012475 Salmonella A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria that utilizes citrate as a sole carbon source. It is pathogenic for humans, causing enteric fevers, gastroenteritis, and bacteremia. Food poisoning is the most common clinical manifestation. Organisms within this genus are separated on the basis of antigenic characteristics, sugar fermentation patterns, and bacteriophage susceptibility.
D013792 Thalidomide A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. Sedoval,Thalomid
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

E P Sampaio, and E N Sarno, and R Galilly, and Z A Cohn, and G Kaplan
October 1995, The Journal of infectious diseases,
E P Sampaio, and E N Sarno, and R Galilly, and Z A Cohn, and G Kaplan
April 1992, Journal of immunology (Baltimore, Md. : 1950),
E P Sampaio, and E N Sarno, and R Galilly, and Z A Cohn, and G Kaplan
October 1992, The Annals of otology, rhinology & laryngology. Supplement,
E P Sampaio, and E N Sarno, and R Galilly, and Z A Cohn, and G Kaplan
November 2003, The Journal of investigative dermatology,
E P Sampaio, and E N Sarno, and R Galilly, and Z A Cohn, and G Kaplan
December 2009, Journal of periodontal research,
E P Sampaio, and E N Sarno, and R Galilly, and Z A Cohn, and G Kaplan
October 1996, American journal of respiratory cell and molecular biology,
E P Sampaio, and E N Sarno, and R Galilly, and Z A Cohn, and G Kaplan
August 1999, Molecular cell biology research communications : MCBRC,
E P Sampaio, and E N Sarno, and R Galilly, and Z A Cohn, and G Kaplan
July 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
E P Sampaio, and E N Sarno, and R Galilly, and Z A Cohn, and G Kaplan
December 1991, Lipids,
E P Sampaio, and E N Sarno, and R Galilly, and Z A Cohn, and G Kaplan
June 1992, European journal of immunology,
Copied contents to your clipboard!